We report long-term evolution of endocrine functions and the results of GH treatment in 35 patients (26 male and 9 female) with pituitary stalk interruption. At diagnosis, mean chronological age was 4.8 ± 2.7 years, mean SDS for height –3.1 ± 0.8 with a bone age retardation of 2.3 ± 1.3 years and a mean SDS for growth velocity of –0.5 ± 1.1; 80% presented complete GH deficiency (GHD) and 20% partial GHD; thyroid deficiency was present in 47.1% of children with complete GHD but absent in all partial GHD. Diagnosis was made during the first months of life in only 2 patients while 23% presented with severe neonatal distress; neonatal signs were only observed in the group with pituitary height below 2 mm (45.7% of patients). GHD was isolated in 40.6% of patients below 10 years while multiple hormone deficiencies was consistent at completion of growth in all patients. Height gain was significantly higher in patients who started GH treatment before 4 years (p = 0.002). GH treatment is very effective: in 13 patients, final height was –0.4 ± 1.0, total height gain 3.2 ± 1.2 and distance to target height –0.3 ± 1.6 SDS.

Keywords:
Pituitary stalk interruption syndrome, Growth hormone, Growth hormone deficiency
1.
Fujisawa I, Kikuchi K, Nishimura K, Togashi K, Itoh K, Nama S: Transection of the pituitary stalk: development of an ectopic posterior lobe assessed with MR imaging. Radiology 1987;165:487–489.
2.
Fujisawa I, Asato R, Nishimura K, Togashi K, Itoh K, Nakano Y, Itoh H, Hashimoto N, Takeuchi J, Torizuka K: Anterior and posterior lobes of the pituitary gland: assessment by 1.5 T MR Imaging. J Comput Assist Tomogr 1987;11:214–220.
3.
Coutant R, Rouleau S, Despert F, Magontier N, Loisel D, Limal JM: Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings. J Clin Endocrinol Metab 1987;86:4649–4654.
4.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
5.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:64–66.
6.
Greulich W, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford, Stanford University Press, 1959.
7.
Argyearopoulou M, Perignon F, Brauner R, Brunelle F: Magnetic resonance imaging in the diagnosis of growth hormone deficiency. J Pediatr 1992;120:886–891.
8.
Usher R, Mc Lean F: Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969;74:901–910.
9.
Ranke MB, Lindberg A, Chatelain P, Wiltron P, Cutfiels W, Albertsson-Wikland K: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in pubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab 1999;102:342–345.
10.
Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, Severy F: Growth Hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab 1999;84:1324–1328.
11.
Huet F, Carel JC, Nivelon JL, Chaussain JL: Long-term results of GH therapy in GH-deficient children treated before 1 year of age. Eur J Endocrinol 1999;140:29–34.
12.
Boersma B, Rikken B, Wit JM: Catch-up growth in early treated patients with growth hormone deficiency: Dutch growth hormone working group. Arch Dis Child 1995;72:427–431.
13.
Guyda HJ: Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84:4307–4316.
14.
Tauber M, Moulin P, Pienkowski C, Jouret B, Rochiccioli P: Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997;82:352–356.
15.
Coste J, Letrait M, Carel JC, Tresca JP, Chatelain P, Rochiccioli P Chaussain JL: Long term results of GH treatment in short stature children: a population register-based study. BMJ 1997;315:708–713.
16.
Carel JC, Ecosse E, Nicolino M, Tauber M, Léger J, Cabrol S, Bastie-Sigeac I, Chaussain JL, Coste J: Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. BMJ 2002;325:70.
17.
Barbeau C, Jouret B, Gallegos D, Sevely A, Manelfe C, Oliver I, Pienkowski C, Tauber MT, Rochiccioli P: Syndrome d’interuption de la tige pituitaire. Arch Pédiatr 1998;5:274–279.
18.
Nagel BHP, Palmbach M, Petersen D, Ranke MB: Magnetic resonance images of 91 children with different causes of short stature: pituitary reflects growth hormone secretion. Eur J Pediatr 1997;156:758–763.
19.
Bozzola M, Adamsbaum C, Biscaldi I, Zecca M, Cisterino M, Genovese E: Role of magnetic resonance imaging in the diagnosis and prognosis of growth hormone deficieny. Clin Endocrinol Oxf 1996;45:21–26.
20.
Chen S, Leger J, Carel C, Hassan M, Czernichow P: Growth hormone deficiency with ectopic neurohypophysis: anatomical variations and relationship between the visibility pituitary stalk asserted by magnetic resonance imaging and anterior pituitary function. J Clin Endocrinol Metab 1999;84:2408–2413.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.